UNSPSC 51373324: Aspirin/caffeine/ipecac/opium

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.

UNSPSC 51373324 Aspirin/caffeine/ipecac/opium is a Commodity code that in recent state and local procurement activity does not map cleanly to its nominal scope. The three recent opportunities posted under this code involve naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products — none of which align with the code's stated drug combinations. State and local buying offices appear to use this code as a catch-all taxonomy placeholder for pharmaceutical and opioid-related health interventions rather than for the specific opium-based formulations the code name describes. The issuing bodies span county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and regional cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon).

Recent activity concentrates in Florida and Texas, with multi-state reach through MMCAP. Seminole County posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually on a competitive bid basis, with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission released Request for Information HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking detailed responses about direct contracting capacity outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 in January 2026 with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities, requiring vendors to maintain relationships with authorized wholesalers and comply with current Good Manufacturing Practices and Drug Supply Chain Security Act standards. The code shows limited recent activity aligned to its nominal pharmaceutical composition; pursuit depends on confirming whether your firm's actual product line matches the health-intervention focus of current buyers rather than the code's stated formulation.